Not a good buy right now: trend is decisively bearish (SMA_200 > SMA_20 > SMA_5) with weakening momentum (MACD histogram negative and expanding).
Price (3.14) is sitting just above key support S1 (3.126); if that breaks, the next support is ~2.928 (S2), implying near-term downside risk outweighs upside for an impatient buyer.
No Intellectia edge today (no AI Stock Picker / SwingMax signal), and pattern-based stats also lean negative over 1W–1M.
With no near-term catalysts (no news) and deteriorating YoY losses, the setup is “avoid/exit,” not “buy now.”
Momentum: MACD histogram -0.0388 below zero and negatively expanding → downside momentum strengthening.
RSI: RSI_6 at 21.468 suggests oversold conditions (bounce possible), but oversold can persist in strong downtrends.
Levels: Pivot 3.447 overhead resistance; immediate support S1 3.126 (very close to current 3.14). Upside resistances: 3.769 (R1), 3.967 (R2). Downside support: 2.928 (S2).
Short-horizon bias from similar patterns: ~80% chance of slight drift lower next day and ~-2.5% over the next week/month → aligns with bearish tape.
Positive Catalysts
Oversold RSI can fuel a short-term technical bounce, especially with price near S1 support (3.126).
Small post-market uptick (+0.65%) hints at minor dip-buying interest, though not confirmed.
Neutral/Negative Catalysts
Pattern-based forward expectation is negative over 1W–1M.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 0 (no YoY improvement indicated).
Profitability: Net income -3,429,124, down -29.23% YoY (losses worsened).
EPS: -1.01, down -76.94% YoY (material deterioration).
Overall: Financials show weakening earnings power with no revenue base, which typically pressures sentiment in risk-off tapes.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so no confirmed recent Street upgrades/downgrades to support a near-term re-rating.
Wall Street-style framework (based on provided data): Pros—possible oversold bounce near support. Cons—downtrend momentum + deteriorating YoY losses + no catalysts; the cons dominate for a “buy now” decision.
Influential/political flow: No recent congress trading data available; hedge funds and insiders are reported neutral with no significant recent trends.
Wall Street analysts forecast IMNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMNN is 12 USD with a low forecast of 12 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast IMNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMNN is 12 USD with a low forecast of 12 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.070
Low
12
Averages
12
High
12
Current: 3.070
Low
12
Averages
12
High
12
D. Boral Capital
Jason Kolbert
Buy
to
Hold
downgrade
AI Analysis
2025-05-19
Reason
D. Boral Capital
Jason Kolbert
Price Target
AI Analysis
2025-05-19
downgrade
Buy
to
Hold
Reason
D. Boral Capital analyst Jason Kolbert downgraded Imunon to Hold from Buy without a price target. The company announced "encouraging" six-month follow-up data from its Phase 1 COVID-19 vaccine study, but the update is immaterial to the investment thesis, which remains centered on Imunon's ovarian cancer program, the analyst tells investors in a research note. The firm says the "more pressing development" is the recently filed prospectus for potentially dilutive financing that could create a significant number of new shares. Given the scale of dilution and uncertainty around shareholder approval, D. Boral downgraded the stock.
Boral Capital
D. Boral
Buy
downgrade
$29 -> $17
2025-05-13
Reason
Boral Capital
D. Boral
Price Target
$29 -> $17
2025-05-13
downgrade
Buy
Reason
D. Boral Capital lowered the firm's price target on Imunon to $17 from $29 and keeps a Buy rating on the shares. The firm now anticipates a series of dilutive financings that are likely to exceed its prior expectations. Imunon has entered a pivotal new phase in its development with the initiation of the Phase 3 OVATION 3 trial evaluating IMNN-001, its lead DNA-based immunotherapy candidate, in newly diagnosed advanced ovarian cancer, the analyst tells investors in a research note. With only $2.9M in cash as of March 31, the company's "financial position remains precarious," contends D. Boral.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMNN
